The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | PD-L1 inhibition in gastroesophageal junction cancer
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the promising post hoc analyses from randomized clinical trials and Phase II non-randomized trials investigating anti-PD-L1 treatments for gastroesophageal junction (GEJ) tumors. Such studies show impressive overall response rates and a low rate of early disease progression in patients with microsatellite instable (MSI) gastroesophageal junction tumors. In this population, there are the highest ever-recorded long-term outcomes reported to date, and single-agent immunotherapy may also be an option. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi-Sankyo; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role – Amgen; Bayer; GlaxoSmithKline; Janssen; Merck Serono; MSD Oncology; Rottapharm Biotech; SERVIER; Takeda
Research Funding – Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst)
Travel, Accommodations, Expenses – Merck Serono; Pierre Fabre
